Skip to Content
Morningstar
Get 14 Days Free

Stericycle Inc SRCL

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

We’ve Upgraded Stericycle’s Moat Rating To Narrow As Turnaround Efforts Gain Traction

Analyst Note

| Brian Bernard, CFA, CPA |

After taking a fresh look at medical waste leader Stericycle, we've upgraded the firm's moat rating to narrow from none. While we have long believed the firm's core medical waste business was competitively advantaged, poor capital allocation decisions and deficient acquisition integration led to deteriorating financial performance and economic value destruction. Our prior no-moat rating was based on our lack of conviction that Stericycle was more likely than not to earn excess returns over the next decade.

Read Full Analysis

Company Profile

Business Description

Stericycle is the largest provider of medical waste disposal and data destruction (primarily paper shredding) services in the United States. Its next closest national competitor in the medical waste disposal space is Sharps Compliance, which generated $51 million of sales in 2020 (about 3% of Stericycle's global regulated waste and compliance revenue). Stericycle's data destruction business (Shred-It) is about twice the size of its closest competitor (Iron Mountain's information destruction segment). Stericycle has a global presence, with about 20% of its revenue earned outside North America. Globally, the company has 188 transfer sites, 232 processing facilities, and 7,800 trucks.

Contact
2355 Waukegan Road
Bannockburn, IL, 60015
T +1 847 367-5910
Sector Industrials
Industry Waste Management
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Distressed
Employees 15,000

Related

Our Picks
33 Undervalued Stocks
Here are our analysts' top ideas in each sector at the third quarter's end.
Susan Dziubinski
Quarter-End Insights
Industrials: Sector Fairly Valued Overall, but Industrial Distributors Look Compelling
Industrials has outperformed despite signs of an economic slowdown and fears over tariffs.
Keith Schoonmaker
Quarter-End Insights
Industrials: Bargains Among Industrial Distributors, Farm & Construction Machinery
The stocks in this sector look fairly valued, and tariffs seem to be only a minor threat.
Keith Schoonmaker
Fund Spy
A Simple Yet Well-Executed Approach to Dividend-Paying Stocks
At Silver-rated T. Rowe Price Equity Income, yield, valuation, quality of management, and company fundamentals all matter.
Katie Rushkewicz Reichart
Stock Strategist
Pricing Reset Needles Stericycle's Growth, but Shares Undervalued
Small-quantity rollbacks won't weigh on the stock indefinitely.
Matthew Young
US Videos
A Buying Opportunity for Narrow-Moat Stericycle
The medical-waste management leader is trading at a discount but will face heightened volatility in the year ahead.
Matthew Young
Our Picks
13 New Stocks in the Wide Moat Focus Index
The Morningstar Wide Moat Focus Index has added several semiconductor stocks and asset managers, among others, to its roster.
Susan Dziubinski
Our Picks
10 Newest Stocks in the Wide-Moat Focus Index
The Morningstar Wide Moat Focus Index made room for some undervalued consumer defensive stocks in June.
Karen Wallace
US Videos
Headwinds for Stericycle but Shares Undervalued
The narrow-moat firm offers attractive upside potential for value investors who can handle volatility.
Matthew Young
Stock Analyst Update
Stericycle: Restructuring Weighs, Shares Attractive
Restructuring efforts will yield material longer term benefits, but at today's price, shares offer an attractive margin of safety to patient investors willing to stomach near-term volatility.
Matthew Young
Market Update
What a Thriving Global Economy Means for Stocks
For the first time since the recession, all OECD-tracked countries are growing at the same time. And that presents opportunities.
Bryan Borzykowski
Our Picks
6 New Stocks in the Wide Moat Focus Index
The Morningstar Wide Moat Focus Index adds some healthcare and tech, eschews some financial services stocks.
Karen Wallace
Our Picks
32 Undervalued Stocks
With 2017 in the books, our equity analysts name their best ideas in every sector.
Karen Wallace
Quarter-End Insights
Industrials: Pockets of Uncertainty Present a Few Opportunities
Industrials are the second-most-expensive sector we cover, but these picks can reward investors.
Eric Anfinson
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Nov. 17.
Morningstar.com
Our Picks
25 Cheap Stocks
Whether you prefer higher-quality companies or more speculative fare, there's plenty of good ideas on our list.
Karen Wallace
Stock Strategist
Stericycle Sell-Off Overdone
We think the shares currently offer a significant margin of safety to investors.
Barbara Noverini
Our Picks
The 15 Cheapest Stocks in the Wide Moat Focus Index
These high-quality names are on sale.
Susan Dziubinski
US Videos
4 Cheap Picks in Our Wide Moat Focus Index
Stericycle, Express Scripts, Allergan, and Disney have strong competitive advantages and are trading at a discount to our fair value estimates.
Karen Wallace
Our Picks
6 New Stocks in the Wide Moat Focus Index
The Morningstar Wide Moat Focus Index scoops up some asset managers and jettisons some real estate stocks.
Karen Wallace

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.